Natco Pharma declares ₹1.50 interim dividend; record date Aug 20

0 min read | Published on 14 Aug 2026, 02:38 PM |Updated on 14 Aug 2026, 04:10 PM

Reviewed by

Naman SScanX News Team

Key Highlights

Natco Pharma Limited has declared an interim dividend of ₹1.50 per share for FY27, representing a 75% payout on its ₹2 face value shares. The record date is August 20, 2026, with payments starting August 26. The board also approved a fund raise of up to ₹20 billion.

*this image is generated using AI for illustrative purposes only.

Natco Pharma declared an interim dividend of ₹1.50 per equity share for the financial year 2026-27. The company's board of directors also approved a fund raising initiative of up to ₹20 billion.

Corporate Actions

The dividend payout reflects the company's commitment to returning value to shareholders. Simultaneously, the approval for raising funds indicates strategic planning for capital allocation or debt management.

Key Decisions

Interim dividend: ₹1.50 per share
Fund raising approval: Up to ₹20 billion

These actions were confirmed during the recent board meeting.

Dividend Details

The Board of Directors, in its meeting held on August 14, 2026, declared the interim dividend at a rate of 75% on the face value of ₹2 per share. Shareholders whose names appear on the register as of the record date will be eligible for the payment.

Detail	Information
Record Date:	August 20, 2026
Payment Start Date:	August 26, 2026
Dividend Per Share:	₹1.50
Face Value:	₹2
Payout Ratio:	75%

The payment of the interim dividend will begin from August 26, 2026.

Historical Stock Returns for Natco Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.15%	-3.38%	-10.81%	-13.34%	-4.97%	-16.08%

What specific strategic initiatives or acquisitions is Natco Pharma planning to fund with the approved ₹20 billion capital raise?

How might the simultaneous dividend payout and large-scale fund raising impact Natco Pharma's debt-to-equity ratio and credit ratings?

Will the company utilize equity, debt, or hybrid instruments for the ₹20 billion fundraising, and what are the implications for existing shareholders' dilution?

Natco Pharma

View Company Insights

View All News

Natco Pharma Q1 Results: Net profit falls 56% YoY to ₹2.1 billion

1 min read | Published on 14 Aug 2026, 02:37 PM |Updated on 14 Aug 2026, 02:37 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Natco Pharma's Q1 results show a major downturn with net profit dropping 56% YoY to ₹2.1 billion and revenue falling 45% to ₹7.3 billion. EBITDA margin compressed to 25.4% from 42.97%, indicating significant operational pressure as costs did not fall in line with revenue.

*this image is generated using AI for illustrative purposes only.

Natco Pharma reported a significant contraction in its first-quarter financial performance, with both top-line and bottom-line figures declining sharply compared to the same period last year.

The company’s net profit for the quarter stood at ₹2.1 billion, down from ₹4.8 billion recorded in the corresponding period of the previous fiscal year. This represents a substantial year-on-year decline in profitability.

Financial Performance

Revenue also witnessed a steep drop, falling to ₹7.3 billion from ₹13.3 billion in the prior year quarter. The decline in sales was accompanied by a compression in operating margins.

Metric:	Q1 Current	Q1 Prior Year	Change
Revenue:	₹7.3 billion	₹13.3 billion	-45.1%
EBITDA:	₹1.86 billion	₹5.7 billion	-67.4%
EBITDA Margin:	25.4%	42.97%	-17.57 pts
Net Profit:	₹2.1 billion	₹4.8 billion	-56.3%

EBITDA for the quarter was ₹1.86 billion, a significant decrease from ₹5.7 billion in the previous year. Consequently, the EBITDA margin contracted to 25.4% from 42.97% recorded earlier.

What the Numbers Show

The data reveals a divergence between the rate of revenue decline and the sharper contraction in operating profits. While revenue fell by approximately 45%, EBITDA declined by nearly 67%. This suggests that cost structures or input prices may not have reduced proportionately with the drop in sales volume, leading to significant margin pressure during the quarter.

Historical Stock Returns for Natco Pharma